Does endothelin-1 regulate vascular tone through endothelin A receptors?

Endothelin-1 (ET-1) is an established regulator of vascular tone, but an elevated endothelin-A receptor (ETAR/EDNRA) antibody result is not, by itself, a functional or clinically diagnostic finding.

Clinical and physiological evidence

• ET-1-induced vasoconstriction is mediated predominantly through ETA receptors on vascular smooth muscle. In randomized placebo-controlled human forearm studies, the selective ETA antagonist BQ-123 substantially attenuated—and at higher doses nearly abolished—ET-1-induced vasoconstriction, while reducing peripheral vascular resistance and mean arterial pressure.
• ETA signaling is therefore an important vasoconstrictor pathway, including in pulmonary vascular disease. Its contribution to resting vascular tone is nevertheless context- and vascular-bed-dependent; ETA is not the sole determinant of tone, and ETB receptor effects can be vasodilatory or vasoconstrictive depending on cellular location.

Mechanistic interpretation

• ETA activation engages Gq/11–phospholipase C signaling, generating IP3/DAG, increasing intracellular calcium, and activating calcium–calmodulin/myosin-light-chain kinase and Rho-kinase pathways that contract vascular smooth muscle.
• A binding ELISA cannot show whether ETAR antibodies activate this pathway, have no functional effect, or inhibit ET-1 signaling. Agonist-like activity requires receptor-specific cell assays measuring calcium flux or ERK/MAPK responses, with negative-cell and receptor-blocking controls. Antagonism specifically requires demonstration that antibodies suppress ET-1-induced, ETA-dependent signaling.

Clinical interpretation

• Observational associations exist—for example, anti-ETAR antibodies are more frequent in SLE-associated pulmonary arterial hypertension and modestly correlate with pulmonary pressure—but they do not prove causality.
• Functional assays are not standardized for routine clinical care, and neither an elevated binding titer nor in-vitro receptor activity alone establishes diagnosis, prognosis, or a treatment indication.

Bottom line

• ETA-mediated ET-1 signaling is a well-established vasoconstrictor mechanism. Elevated ETAR-binding antibodies should be interpreted only as antigen recognition until controlled functional testing—and patient-level outcome validation—clarifies their biological and clinical significance.